This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 1998-2014.
Location History:
- Tokushima, JP (1998)
- Osaka, JP (2012 - 2014)
Company Filing History:
Years Active: 1998-2014
Title: Kenji Tsujimae: Innovator in Benzodiazepine Compounds
Introduction
Kenji Tsujimae is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of benzodiazepine compounds. With a total of 3 patents to his name, Tsujimae's work has garnered attention for its potential applications in medical science.
Latest Patents
One of Tsujimae's latest patents involves a novel benzodiazepine compound and pharmaceutical composition. This invention provides a compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The benzodiazepine compound is represented by General Formula (1), wherein R, R, R, and R are each independently hydrogen or lower alkyl. Additionally, R and R may be linked to form lower alkylene, while R and R are each independently hydrogen or an organic group.
Career Highlights
Tsujimae is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing the understanding and application of benzodiazepine compounds in medicine.
Collaborations
Throughout his career, Tsujimae has collaborated with notable colleagues, including Toshiyuki Onogawa and Hokuto Yamabe. These collaborations have further enriched his research and development efforts.
Conclusion
Kenji Tsujimae stands out as a prominent inventor in the pharmaceutical industry, particularly for his advancements in benzodiazepine compounds. His contributions continue to influence the field and hold promise for future medical applications.